Ipsen plans to invest a further €15 million in its Blanchardstown site between 2023 and 2026, it said. The company has expanded its workforce at the facility by 20 per cent since 2019 and is focused on driving continued research and innovation through its R&D division, having grown its team of chemists and analysts by 10 per cent over the past two years.
“It’s great to see a biopharmaceutical company which has been here for over 30 years continuing to invest and grow in Ireland, particularly when the goal is to help more patients achieve a better quality of life through its medicines,” said Mr Varadkar, as he welcomed the site launch and investment announcement.
“We hope to continue building Ipsen Ireland as an important pharmaceutical manufacturing and development site within Europe. Now we welcome the continued efforts of the Irish Government to invest in the innovative medicines that will enable Ipsen Ireland to transform even more patients’ lives.”